Phase III Study Failure Clouds Future Of Avanir’s Alzheimer’s Agitation Candidate

Otsuka’s Avanir hit by failed second trial in Phase III program with candidate for agitation associated with Alzheimer’s, prompting a re-think of development plans and potentially helping rivals in a high-need indication.